Search

Displaying results 3861 - 3870 of 10000 in total
  1. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  2. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    [Adefovir] (Hepsera) is an acyclic phosphonate analogue of adenine that is used to treat hepatitis B virus. … The novel prodrug is highly stable in both plasma and tissues and demonstrated potent preclinical and clinical anti-HBV activity.

  3. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    In addition, unlike currently marketed opioids, CR665 does not produce inhibition of intestinal transit (ileus), induce respiratory depression, or elicit signs of euphoria or addiction in animal models … In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound.

  4. Drug

    Nisin Z

    go.drugbank.com/drugs/DB19122
    Investigational

    Nisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in

  6. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  7. Drug

    Thyroglobulin

    go.drugbank.com/drugs/DB01584
    ApprovedWithdrawn

    Thyroglobulin (also known as Tg) is an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3).

  8. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  9. Drug

    Ibrigampar

    go.drugbank.com/drugs/DB05490
    Investigational

    AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.

  10. Drug

    Gaboxadol

    go.drugbank.com/drugs/DB06554
    Investigational

    Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives. … Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing